Sort
15,273 grants matching “antimicrobial resistance”
Drug Discovery from Slow Growing and Rare Microbial Species
$981,599Amy Lynn Spoering · Novobiotic Pharmaceuticals, Llc · R44 · FY2015 · AI
Improving Antimicrobial Prescribing Practices in the Neonatal Intensive Care Unit
$981,543Lisa Saiman · Columbia University Health Sciences · R01 · FY2011 · NR
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo
$980,388Allen R. Comer · Stratatech Corporation · R44 · FY2012 · AI
Dual Function Catheter to Prevent Thrombus and Infection
$980,319Jennifer Ann Neff · Allvivo Vascular, Inc. · R44 · FY2012 · DK
Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds
$980,093Manav Mehta · Gel4med, Inc. · R44 · FY2021 · GM
Therapy Against Recalcitrant C. albicans Infection
$979,417Thomas A Dahl · Arietis · R44 · FY2012 · AI
Development and Formulation of Broad Spectrum Antimicrobials for Biodefense
$979,210Richard A Slayden · Colorado State University · U01 · FY2009 · AI
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
$979,174David B. Weiner · Wistar Institute · R01 · FY2022 · AI
Development and Formulation of Broad Spectrum Antimicrobials for Biodefense
$978,895Richard A Slayden · Colorado State University · U01 · FY2010 · AI
Molecular Antibiotic Resistance Arrays for clinical microbiology laboratories
$978,843Paul Stephen Keim · Translational Genomics Research Inst · R01 · FY2012 · AI
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo
$978,425Allen R. Comer · Stratatech Corporation · R44 · FY2013 · AI
Novel Strategies to Clear Bacteria from the CF Lung
$977,764Saira Ahmad · Eldec Pharmaceuticals, Inc. · R44 · FY2023 · HL
Antimicrobial Oligomers for BioDefense and Emerging Food Borne Infectious Disease
$977,658Gregory N. Tew · University Of Massachusetts Amherst · U01 · FY2009 · AI
Preclinical development of Novo29, a new antibiotic
$977,463Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2021 · AI
Exploration, conservation, & development of marine biodiversity in Fiji and the S
$977,212Mark E Hay · Georgia Institute Of Technology · U19 · FY2016 · TW
Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing
$977,172Paul Rhodes · Specific Diagnostics, Inc. · R44 · FY2021 · AI
Validating establishment of functional safety in skin interface with deeply porous transcutaneous pylon for direct skeletal attachment of limb prostheses
$976,440Mark Pitkin · Poly-Orth International · R44 · FY2021 · AR
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy
$975,586Frank H. Ebetino · Biovinc, Llc · R44 · FY2021 · AI
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?
$975,370Nader Shaikh · University Of Pittsburgh At Pittsburgh · U01 · FY2016 · AI
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?
$975,370Nader Shaikh · University Of Pittsburgh At Pittsburgh · U01 · FY2017 · AI
Novel polymeric materials with improved durability in the oral environment: tailoring responses to host and bacterial enzymes with anti-proteolytic and ecology-based antimicrobial approaches.
$974,310Carmem S. Pfeifer · Oregon Health & Science University · R35 · FY2021 · DE
Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections
$973,816Victor Nizet · University Of California, San Diego · R01 · FY2014 · AI
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease
$973,438Eileen M. Barry · University Of Maryland Baltimore · U19 · FY2023 · AI
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?
$971,785Nader Shaikh · University Of Pittsburgh At Pittsburgh · U01 · FY2019 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** ERSISTENCE OF ANTIMICROBIAL RESISTANCE (AMR) IN LIVESTOCK POPULATIONS, FACILITIES AND SYSTEMS IS A CRITICAL CHALLENGE FOR U.S. PRODUCERS AND PUBLIC HEALTH. WHILE JUDICIOUS ANTIMICROBIAL USE MAY HELP TO DECREASE AMR IN THE LONG-TERM, NEW APPROACHES ARE NEEDED TO MITIGATE PERSISTENCE IN THE SHORT- AND MEDIUM-TERM. THIS IS ESPECIALLY TRUE FOR AMR MITIGATION AFTER ANTIBIOTIC EXPOSURES SUCH AS METAPHYLAXIS, WHICH ARE CRUCIAL FOR ANIMAL WELFARE.AMR DYNAMICS ARE DRIVEN BY MICROBIAL ECOLOGY AND EVOLUTION. THEREFORE, INTERVENTIONS THAT TARGET MICROBIOME RECOVERY AFTER ANTIBIOTIC EXPOSURE MAY HELP TO MITIGATE AMR DEVELOPMENT AND PERSISTENCE. TO TEST THIS HYPOTHESIS, WE PROPOSE A FIELD TRIAL TO INVESTIGATE THE IMPACTS OF POST-PROCESSING COMMINGLING AND A HIGH-FIBER POST-WEANING DIET ON AMR DYNAMICS AFTER METAPHYLAXIS IN SWINE. THROUGH MULTIVARIABLE MODELING AND NETWORK ANALYSIS OF TIME-SERIES METAGENOMIC DATA, WE WILL IDENTIFY WHEN AND HOW COMMINGLING AND DIET REDUCE AMR; AND WHICH MICROBIAL TAXA SIGNIFICANTLY ALTER AMR DYNAMICS.THESE RESULTS WILL GUIDE PRACTICAL AND EVIDENCE-BASED RECOMMENDATIONS FOR MANAGEMENT OF SWINE AFTER ANTIBIOTIC EXPOSURES; AND WILL PROVIDE A SPRINGBOARD FOR FURTHER MICROBIOME-BASED AMR MITIGATION STRATEGIES. TO HELP SUSTAIN THIS EFFORT, WE PROPOSE AN OPEN RESEARCH PORTAL WITH COMPANION TUTORIALS AND WORKSHOPS, WHICH WILL HELP TO REMOVE TECHNICAL BARRIERS AND PROMOTE INTEGRATION OF MULTI-OMIC DATA INTO EXISTING AMR RESEARCH PROGRAMS.
$971,166Regents Of The University Of Minnesota · · FY2021 · National Institute of Food and Agriculture